Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharma Mar SA ( (ES:PHM) ) just unveiled an announcement.
Pharma Mar has received an upgrade of its long-term credit rating from EthiFinance Ratings, moving from “BB+” to “BBB” with a stable outlook. The improved investment-grade rating reflects enhanced credit quality and may lower the company’s financing costs, strengthen its balance sheet flexibility, and support its strategic positioning in the competitive biopharmaceutical sector.
This upgrade could also improve investor confidence and broaden the potential base of institutional lenders and bondholders able to participate in Pharma Mar’s funding. A stronger credit profile may facilitate future investments in research, development, and commercialization, potentially accelerating the company’s pipeline execution and long-term growth prospects.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR104.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
More about Pharma Mar SA
Pharma Mar S.A. is a Spanish biopharmaceutical company based in Colmenar Viejo, Madrid, focused on developing and commercializing oncology and other specialized medicines, often derived from marine resources. The company operates in global pharmaceutical markets, targeting niche therapeutic areas where innovative treatments can command premium pricing and support sustainable growth.
Average Trading Volume: 48,878
Technical Sentiment Signal: Strong Buy
Current Market Cap: €1.59B
Find detailed analytics on PHM stock on TipRanks’ Stock Analysis page.